newsfilter
← Latest News
GlobeNewswire·

Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update

- FDA approval of IDE to conduct a U.S. pilot study exploring the use of Alpha DaRT in patients with recurrent glioblastoma multiforme (GBM), a highly aggressive brain cancer - - Multiple U.S. clinical trials, including